Crinetics Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Crinetics Pharmaceuticalsの CEO はR. Struthersで、 Dec2008年に任命され、 の在任期間は 17.58年です。 の年間総報酬は$ 11.63Mで、 6.2%給与と93.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.14%を直接所有しており、その価値は$ 101.16M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と5.8年です。
主要情報
R. Struthers
最高経営責任者
US$11.6m
報酬総額
| CEO給与比率 | 6.18% |
| CEO在任期間 | 17.6yrs |
| CEOの所有権 | 1.1% |
| 経営陣の平均在職期間 | 5.1yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Jul 10
CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook
Crinetics Pharmaceuticals' analyst fair value estimate has been trimmed from $97 to $90 as analysts recalibrate expectations around the $85 per share cash acquisition by Vertex Pharmaceuticals and the cluster of rating downgrades to Hold or Neutral that now anchor views closer to the agreed deal price. Analyst Commentary Analysts covering Crinetics Pharmaceuticals are now largely treating the stock as a merger arbitrage situation, with ratings concentrated around Hold or Neutral and price targets aligning closely with the agreed US$85 per share cash offer from Vertex Pharmaceuticals.Seeking Alpha • Jul 07
Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know
Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking Alphaナラティブ更新 • Jun 26
CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.分析記事 • Jun 19
Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...分析記事 • May 13
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...Seeking Alpha • Jan 02
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaSeeking Alpha • May 23
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$496m |
| Dec 31 2025 | US$12m | US$719k | -US$465m |
| Sep 30 2025 | n/a | n/a | -US$423m |
| Jun 30 2025 | n/a | n/a | -US$370m |
| Mar 31 2025 | n/a | n/a | -US$328m |
| Dec 31 2024 | US$11m | US$654k | -US$298m |
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
報酬と市場: R.の 総報酬 ($USD 11.63M ) は、 US市場 ($USD 8.29M ) の同規模の企業の平均を上回っています。
報酬と収益: R.の報酬は増加しましたが、会社は利益を上げていません。
CEO
R. Struthers (64 yo)
17.6yrs
在職期間
US$11,628,959
報酬
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 17.6yrs | US$11.63m | 1.14% $ 101.2m | |
| Co-Founder & Chief Scientific Officer | 18.5yrs | US$3.83m | 0.054% $ 4.8m | |
| Chief Financial Officer | 1.4yrs | US$4.45m | 0.0067% $ 596.8k | |
| Chief Information Officer | 1.3yrs | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし | |
| Chief Legal Officer & Corporate Secretary | 5.1yrs | データなし | データなし | |
| Head of Corporate Communications | no data | データなし | データなし | |
| Chief Human Resources Officer | 6.2yrs | データなし | データなし | |
| Chief Endocrinologist | 8.1yrs | US$2.16m | データなし | |
| Head of Intellectual Property | no data | データなし | データなし | |
| Chief Business Officer | 4.3yrs | データなし | データなし | |
| Senior Vice President of Medical Affairs | 2.2yrs | データなし | データなし |
5.1yrs
平均在職期間
61.5yo
平均年齢
経験豊富な経営陣: CRNXの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 17.7yrs | US$11.63m | 1.14% $ 101.2m | |
| Independent Chairman of the Board | 10.8yrs | US$528.62k | 0.11% $ 9.7m | |
| Independent Director | 8.4yrs | US$498.59k | 0.022% $ 1.9m | |
| Independent Director | 5.8yrs | US$500.47k | 0.015% $ 1.4m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.5yrs | US$507.34k | 0.013% $ 1.1m | |
| Independent Director | 8.4yrs | US$493.84k | 0.015% $ 1.4m | |
| Independent Director | 7yrs | US$500.47k | 0.0061% $ 536.7k | |
| Independent Director | 4.3yrs | US$485.47k | 0.015% $ 1.4m | |
| Member of Scientific Advisory Board | 4.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.3yrs | データなし | データなし |
5.8yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: CRNXの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/19 10:48 |
| 終値 | 2026/07/17 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Crinetics Pharmaceuticals, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |